DARPA reveals the teams that'll target superbugs under HEALR project

DARPA has revealed the three teams that will work under its Hearnessing Enzymatic Activity for Lifesaving Remedies (HEALR) program to help develop new medical technologies targeted at “emerging microbial threats.” DARPA seems to be particularly interested in addressing ‘superbugs,’ which refers to bacteria that is resistant to multiple different drugs typically used to treat infections. DARPA’s HEALR program is designed …